1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. HEMOPHILIA MARKET BY DISEASE TYPE
5.1. Introduction
5.2. Hemophilia A
5.3. Hemophilia B
5.4. Others
6. HEMOPHILIA MARKET BY THERAPY
6.1. Introduction
6.2. Replacement Therapy
6.3. Gene Therapy
6.4. Others (Immune Tolerance Induction Therapy etc.)
7. HEMOPHILIA MARKET BY PRODUCT TYPE
7.1. Introduction
7.2. Recombinant Coagulation Factor Concentrates
7.3. Plasma-derived Coagulation Factor Concentrates
7.4. Others (Desmopressin etc.)
8. HEMOPHILIA MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Bayer AG
10.2. BioMarin Pharmaceutical, Inc.
10.3. CSL Behring
10.4. Novo Nordisk
10.5. Pfizer, Inc.
10.6. Roche (Chugai Pharmaceutical Co.)
10.7. Sanofi (Genzyme Corporation)
10.8. Takeda Pharmaceutical (Shire Plc.)
10.9. Grifols
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES